Note of clarification regarding data about the association between the interleukin-1β −31T>C polymorphism and breast cancer risk Yadong WangYan WangLi Li Editorial 05 February 2016 Pages: 415 - 417
Note of clarification regarding data on the association between the interleukin-1β −511C>T polymorphism and breast cancer risk Yadong WangXinwei ChuHaiyu Wang Editorial 18 February 2016 Pages: 419 - 421
Natural history of age-related lobular involution and impact on breast cancer risk Derek C. RadiskyDaniel W. VisscherAmy C. Degnim Preclinical study Open access 04 February 2016 Pages: 423 - 430
Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin Marcia R. CampbellHui ZhangCatherine C. Park Preclinical study 09 February 2016 Pages: 431 - 440
High-density lipoprotein of patients with breast cancer complicated with type 2 diabetes mellitus promotes cancer cells adhesion to vascular endothelium via ICAM-1 and VCAM-1 upregulation Xiaoqin HuangDan HeLemin Zheng Preclinical study 12 February 2016 Pages: 441 - 455
HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline Yao-Shan FanCarmen E. CasasIsildinha M. Reis Preclinical study 19 February 2016 Pages: 457 - 462
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer Giuseppe VialeLeen SlaetsFatima Cardoso Clinical trial Open access 28 January 2016 Pages: 463 - 469
The effect of resistance training on markers of immune function and inflammation in previously sedentary women recovering from breast cancer: a randomized controlled trial Amanda D. HagstromPaul W. M. MarshallSimon Green Clinical trial 28 January 2016 Pages: 471 - 482
Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor Brandon S. SheffieldZuzana KosStephen K. L. Chia Clinical trial 04 February 2016 Pages: 483 - 490
Effect of a randomized controlled exercise trial on bone outcomes: influence of adjuvant endocrine therapy M. Tish KnobfSangchoon JeonKarl Insogna Clinical trial 05 February 2016 Pages: 491 - 500
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) Alice C. ShapiroSusan A. AdlisRachel E. Lerner Clinical Trial 11 February 2016 Pages: 501 - 512
Comparison of intra-operative specimen mammography to standard specimen mammography for excision of non-palpable breast lesions: a randomized trial Cynthia L. MillerSuzanne B. CoopeyMichelle C. Specht Clinical trial 12 February 2016 Pages: 513 - 519
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies Amy Jo ChienAlyson CockerillPamela N. Munster Clinical trial 13 February 2016 Pages: 521 - 530
Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium Mia M. GaudetMyrto BarrdahlPeter Kraft Epidemiology 23 January 2016 Pages: 531 - 540
Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community Michael J. HassettWei JiangRinaa S. Punglia Epidemiology 03 February 2016 Pages: 541 - 549
Impact of very low physical activity, BMI, and comorbidities on mortality among breast cancer survivors Sandahl H. NelsonCatherine R. MarinacJohn P. Pierce Epidemiology 10 February 2016 Pages: 551 - 557
Associations of sex steroid hormones with mortality in women with breast cancer Catherine DugganFrank StanczykAnne McTiernan Epidemiology 10 February 2016 Pages: 559 - 567
Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers Ines Vaz-LuisMelissa E. HughesNancy U. Lin Epidemiology 11 February 2016 Pages: 569 - 578
Healthy dietary patterns and risk of breast cancer by molecular subtype Kelly A. HirkoWalter C. WillettA. Heather Eliassen Epidemiology 12 February 2016 Pages: 579 - 588
Clinical predictors of long-term survival in HER2-positive metastatic breast cancer Pooja MurthyKelley M. KidwellN. Lynn Henry Epidemiology 13 February 2016 Pages: 589 - 595
Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens D. G. EvansF. LallooA. Howell Epidemiology 18 February 2016 Pages: 597 - 601
Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm Lynn JongenRobert ParidaensPatrick Neven Brief Report 11 February 2016 Pages: 603 - 607
Erratum to: Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer Shao-Wen HungChing-Feng ChiuShu-Mei Liang Erratum 15 February 2016 Pages: 609 - 612
Erratum to: Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option Ziyan Yuan PessettoYing YanAmarnath Natarajan Erratum 16 February 2016 Pages: 613 - 613
Erratum to: CXCL13–CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis Subir BiswasSuman SenguptaArindam Bhattacharyya Erratum 17 February 2016 Pages: 615 - 616
Erratum to: Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice Eun-Young GilUk-Hyun JoKyong Hwa Park Erratum 18 February 2016 Pages: 617 - 618
Erratum to: A nomogram based on mammary ductoscopic indicators for evaluating the risk of breast cancer in intraductal neoplasms with nipple discharge Zhen-Qiang LianQi WangSi-Mei Xie Erratum 19 February 2016 Pages: 619 - 619
